Phaseline

Companies › Nkarta

Nkarta: clinical trials, targets and expected readouts

1 active drug program in 3 registered trials: 3 Phase 1; Immunology, Oncology; next expected readout Apr 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
NKX019
CD19-directed CAR NK cell therapy
CD19Phase 1Lupus Nephritis; Systemic Sclerosis; Lymphoma, Non-HodgkinApr 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06557265NKX019Phase 1Lupus NephritisImmunologyApr 2027
NCT06733935NKX019Phase 1Systemic SclerosisImmunologyOct 2028
NCT05020678NKX019Phase 1Lymphoma, Non-HodgkinOncologyDec 2038

From the company's SEC filings

Cash and short-term investments of $157m on 2026-09-30; operating cash outflow about $105m a year; runway about 18 months at that burn, to Mar 2028

Press releases filed as 8-K in the last year:

Targets

CD19 (1)

Companies with the same targets

Gilead Sciences Bristol-Myers Squibb Chongqing Precision Biotech Allogene Therapeutics Miltenyi Biomedicine Amgen AstraZeneca Beijing Yongtai Ruike Biotechnology Company Shanghai Ming Ju Biotechnology iCell Gene Therapeutics

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.